Wisam Elmalik
Neurology · Amherst, NYNPI 1942632880
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $201,635 of the $289,108 with a category attached, or 69.7%. 36 manufacturers reported payments, led by Biogen at 33.0% of the total. Reporting peaked in 2022 at $92,462 and has fallen 99.7% since, to $284 in 2025. Among neurology clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 746 payments — averaging $387.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biogen$95K
- EMD Serono, Inc.$77K
- Amgen$49K
- Sanofi$35K
- Novartis$10K
- TG Therapeutics, Inc.$9K
- plus $13K from 30 others
Across 45 payments — averaging $1082.13 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- EMD Serono, Inc.$35K
- Biogen$9K
- Novartis$4K
What the payments were for
- Consulting fees$51,89818%
- Speaking & faculty fees$201,63570%
- Travel & lodging$18,1916%
- Food & beverage$17,1246%
- Education$2610%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biogen | 163 | $95,500 |
| EMD Serono, Inc. | 118 | $77,235 |
| Amgen(2 entities) | 100 | $48,917 |
| Sanofi | 52 | $35,464 |
| Novartis | 60 | $10,010 |
| TG Therapeutics, Inc. | 12 | $9,228 |
| Genentech USA, Inc. | 33 | $7,318 |
| E.r. Squibb & Sons, L.L.C. | 2 | $1,409 |
| MDD US Operations, LLC | 35 | $1,208 |
| AbbVie(2 entities) | 30 | $603 |
| Biohaven Pharmaceutical Holding Company Ltd. | 41 | $315 |
| Bristol Myers Squibb | 17 | $268 |
| Biohaven Pharmaceuticals, Inc. | 4 | $162 |
| Neurocrine Biosciences, Inc. | 9 | $146 |
| Teva Pharmaceuticals USA, Inc. | 7 | $128 |
| Lundbeck LLC | 1 | $112 |
| Avanir Pharmaceuticals, Inc. | 5 | $112 |
| AstraZeneca | 6 | $109 |
| Supernus Pharmaceuticals, Inc. | 5 | $92 |
| CSL Behring | 4 | $91 |
| Pfizer | 5 | $85 |
| Banner Life Sciences, LLC | 4 | $70 |
| Acadia Pharmaceuticals Inc | 4 | $70 |
| Argenx US, Inc. | 3 | $61 |
| Johnson & Johnson | 4 | $58 |
| GE HealthCare | 7 | $55 |
| GRT US Holding, Inc. | 3 | $48 |
| Tanabe Pharma America, Inc. | 3 | $45 |
| Genentech, Inc. | 1 | $40 |
| Otsuka America Pharmaceutical, Inc. | 2 | $40 |
| SK Life Science, Inc. | 1 | $24 |
| Merz Pharmaceuticals, LLC | 1 | $21 |
| Acorda Therapeutics, Inc | 1 | $20 |
| Lilly USA, LLC | 1 | $16 |
| Idorsia Pharmaceuticals US Inc | 1 | $15 |
| Mallinckrodt Hospital Products Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Mavenclad$60,860
- TYSABRI$49,639
- UPLIZNA$47,686
- AUBAGIO$34,088
- TECFIDERA$17,709
- Vumerity$16,659
- MAYZENT$7,903
- Evobrutinib$7,645
- BRIUMVI$7,450
- OCREVUS$6,691
- GOCOVRI$592
- KESIMPTA$470
- NURTEC ODT$122
- VYEPTI$112
- DISEASE STATE$108
How this compares
$289,108 in reported general payments places this provider in the 95th percentile of 1,623 neurology providers in New York.
Other neurology in Amherst
- Nicolas SaikaliAmherst$1.5M
- Jennifer McVigeAmherst$982K
- Bennett MyersAmherst$432K
- Laszlo MechtlerAmherst$347K
- Idan SharonBrooklyn$2.1M
- Allan PerelStaten Island$1.7M
- David KreitzmanCommack$1.5M
- Charles ArgoffAlbany$1.2M
- Stephen KriegerNew York$1.1M
- Robert FeketeHawthorne$1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.